Peptide microarrays have moved well beyond basic epitope mapping and are now embedded across multiple stages of antibody R&D, from target identification to developability assessment. For organizations working at the interface of discovery and translation, the technology offers a unique combination of scale, resolution, and experimental flexibility that is difficult to replicate with structural or cell-based methods alone.  

The following six studies illustrate how peptide microarrays have been applied in the development and refinement of therapeutic antibodies.

1. Mapping the right epitope: How peptide microarrays guide antibody development against tumor blood vessels

Overview: Researchers at Seoul National University identified Doppel, a protein selectively expressed on tumor-associated tip endothelial cells (TipECs), as a promising angiogenesis-specific target for therapeutic antibody development. After generating candidate antibodies against Doppel, they used peptide microarrays to systematically characterize antibody binding properties at the sequence level. Overlapping peptide libraries spanning the full length of the Doppel protein were directly synthesized onto glass slide microarrays, enabling parallel interrogation of all possible linear epitopes. Epitope-level data were then integrated with downstream functional assays, including angiogenesis models, to correlate binding characteristics with biological activity and guide rational candidate selection.

Why this matters: Tumor angiogenesis remains a critical driver of cancer progression, and Doppel’s selective expression on TipECs makes it an attractive target for therapies designed to disrupt tumor vascularization. Identifying antibodies that recognize surface-exposed, functionally relevant epitopes — while excluding those binding inaccessible or structurally irrelevant regions — is essential for maximizing the likelihood of in vivo efficacy. Early specificity assessment through cross-reactive sequence profiling further reduces developability risk. By linking epitope-level binding data to functional outcomes, the study demonstrates how high-resolution antibody characterization can meaningfully accelerate the transition from target discovery to therapeutically validated candidates in complex oncology settings such as tumor-specific vascular targeting.

How peptide microarrays were used: Overlapping peptide libraries covering the complete Doppel protein sequence were directly synthesized onto glass slide microarrays, allowing simultaneous interrogation of antibody binding across all possible linear epitopes. This enabled precise identification of the exact sequence regions recognized by each candidate antibody, providing insight into epitope location, surface accessibility, and potential functional relevance. The microarray data distinguished antibodies binding to biologically meaningful regions from those recognizing structurally inaccessible sequences, supporting rational candidate prioritization. In addition, the platform revealed potential cross-reactive sequence motifs, contributing to early specificity and developability assessment. Microarray-derived epitope information was subsequently integrated with angiogenesis model data to establish correlations between binding characteristics and biological activity.

Reference: Kim, Byoungmo, et al. “Selective Targeting of Tip Endothelial Cells as a Therapeutic Strategy for Tumor Angiogenesis.” Advanced Science (2026): e12975. https://doi.org/10.1002/advs.202512975

2. Inducing therapeutic antibodies via peptide immunogens: A microarray-guided approach to targeting CGRP

Overview: Scientists at Vaxxinity Inc. developed a peptide-based active immunotherapy designed to induce endogenous polyclonal antibodies against calcitonin gene-related peptide (CGRP), a clinically validated migraine target. Rather than administering monoclonal antibodies directly, the approach used a synthetic peptide immunogen to elicit a sustained immune response. Following immunization across multiple preclinical species, serum-derived antibodies were analyzed for binding characteristics, specificity, and functional activity. Peptide microarrays were integrated into this workflow to characterize the fine specificity of the induced antibody response, and the resulting data were combined with functional assays demonstrating binding affinities and pharmacodynamic effects comparable to existing therapeutic monoclonal antibodies, including in vivo inhibition of CGRP-mediated responses.

Why this matters: CGRP is a self-peptide, meaning that inducing a targeted immune response against it requires breaking immune tolerance without triggering broad off-target reactivity — a key challenge in active immunotherapy design. Confirming that the elicited antibody response is tightly focused on the intended epitope is therefore essential for both efficacy and safety. Demonstrating epitope consistency across species adds translational confidence and supports the relevance of preclinical findings for clinical development. This study illustrates the broader potential of active immunotherapy as an alternative to repeated monoclonal antibody administration, and highlights how sequence-resolved specificity data can directly validate immunogen design in self-antigen targeting programs.

How peptide microarrays were used: Peptide microarrays displaying sequences corresponding to CGRP and related motifs were used to map the fine specificity of the antibody response induced by immunization. The arrays enabled detailed characterization of binding profiles at the sequence level, confirming that the immune response was focused on the intended epitope and did not broadly target unrelated sequences. This specificity data supported a favorable safety assessment and validated the immunogen design. The platform additionally enabled cross-species comparison of epitope targeting, providing evidence of reproducibility and translational relevance. Microarray-derived specificity data were subsequently integrated with functional assay results to establish a comprehensive profile linking immunogen design to antibody outcome. 

Reference: Boyd, Justin D., et al. “Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide.” Communications Medicine 5.1 (2025): 145. https://doi.org/10.1038/s43856-025-00870-2

3. Linking epitope specificity to efficacy: Peptide microarrays in mincle antibody development 

Overview: Researchers generated multiple candidate antibodies against macrophage-inducible C-type lectin (Mincle), a receptor implicated in neuroinflammation and neuropathic pain, and evaluated their therapeutic potential in a spinal nerve ligation (SNL) rat model. All candidates demonstrated varying degrees of anti-allodynic efficacy. Peptide microarrays were used to perform high-resolution epitope mapping of each antibody, identifying the precise linear sequences within the extracellular domain of Mincle recognized by each candidate, with epitope lengths ranging from approximately 5 to 15 amino acids. The study further showed that combining the most potent Mincle antibody with a TLR4 inhibitor produced additive effects in reducing neuropathic pain.

Why this matters: Neuropathic pain is a debilitating condition with limited effective treatments, and Mincle’s role in neuroinflammation makes it a compelling therapeutic target. However, identifying which antibody candidate to advance requires more than binding confirmation — it demands an understanding of how epitope location relates to functional outcome. By revealing that antibodies targeting distinct regions of Mincle exhibit markedly different therapeutic effects, this study demonstrates the importance of mechanism-informed candidate selection. The additive effect observed in combination with a TLR4 inhibitor further underscores the therapeutic relevance of targeting the correctly identified epitope, pointing toward rational combination strategies in complex inflammatory pathways.

How peptide microarrays were used: Peptide microarrays were applied to map the binding sites of each candidate antibody at sequence resolution, identifying the precise linear epitopes within the extracellular domain of Mincle recognized by each candidate. This enabled direct correlation between epitope location and in vivo anti-allodynic efficacy, providing a rational basis for prioritizing the most therapeutically effective candidate. Confirmation that recognized epitopes were located in the extracellular domain validated target accessibility, an essential prerequisite for therapeutic intervention. Microarray-derived epitope data were integrated with functional assay results from the SNL rat model, linking binding characteristics to biological activity and supporting mechanism-informed candidate progression beyond simple binding confirmation.

Reference: Kang, Dong Ho, et al. “Anti-allodynic effect of intrathecal antibodies against macrophage-inducible C-type lectin in spinal nerve ligation model in rat.” Heliyon 10.24 (2024). https://doi.org/10.1016/j.heliyon.2024.e40694

4. Epitope-resolved target validation for PSCA antibodies using peptide microarrays

Overview: Researchers at Chonnam National University Hospital and Medical School developed and optimized a fully human therapeutic antibody targeting prostate stem cell antigen (PSCA), a clinically relevant tumor-associated antigen. Following initial antibody discovery via phage display, structure-guided affinity maturation was performed to generate improved variants with enhanced binding properties. Peptide microarrays were then used to characterize antibody–antigen interactions at the sequence level by screening overlapping peptide libraries spanning the PSCA protein, precisely mapping the linear binding regions recognized by each optimized candidate. Microarray-derived epitope data were integrated with structural and biochemical analyses to validate the mechanism of antigen recognition and support lead candidate progression.

Why this matters: PSCA is broadly expressed across prostate cancer tissues with limited expression in normal tissue, making it an attractive therapeutic target — but advancing the right antibody candidate requires more than affinity data alone. Confirming that a selected antibody binds a defined, consistent epitope is essential for reproducibility and downstream development confidence. Assessment of sequence-dependent binding sensitivity additionally provides insight into epitope robustness and potential tolerance to antigen variation, which is relevant for therapeutic performance across patient populations. This study illustrates how integrating epitope mapping into an affinity maturation workflow enables precision candidate selection grounded in structural and functional considerations, rather than binding affinity alone.

How peptide microarrays were used: Overlapping peptide libraries spanning the PSCA protein sequence were screened to precisely map the linear epitopes recognized by each optimized antibody variant. This enabled differentiation between candidates targeting distinct regions of PSCA, supporting selection of those with favorable binding characteristics and potential functional relevance. Confirmation that the lead antibody binds a defined and consistent epitope validated reproducibility critical for downstream development. Assessment of sequence-dependent binding sensitivity provided additional insight into epitope robustness and tolerance to antigen variation. Microarray-derived epitope data were subsequently integrated with structural and biochemical analyses to validate the antigen recognition mechanism and directly inform lead candidate selection within the broader phage display and affinity maturation workflow.

Reference: Chu, Xiaojie, et al. “Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer.” MAbs. Vol. 16. No. 1. Taylor & Francis, (2024). https://doi.org/10.1080/19420862.2024.2387240

5. Epitope-driven selection of CD30-targeting bispecific antibodies using microarray-based mapping

Overview: Researchers at the Medical College of Wisconsin generated a panel of monoclonal antibodies against the extracellular domain of CD30, a clinically validated antigen expressed on Hodgkin lymphoma and other malignancies, and screened them for binding affinity, specificity, and functional activity. Peptide microarrays were used to map the precise epitopes recognized by each candidate, distinguishing antibodies targeting different epitope clusters across the antigen. Two lead candidates with unique epitope profiles — distinct from those of clinically used antibodies — were subsequently engineered into CD30×CD3 bispecific formats capable of simultaneously engaging CD30 on tumor cells and CD3 on T cells. Functional assays confirmed that epitope choice directly influenced cytotoxic potency, with the lead candidate demonstrating superior tumor cell killing across multiple CD30-positive cell lines.

Why this matters: CD30 is an established immunotherapy target, but existing antibody-based approaches such as brentuximab vedotin face limitations including toxicity and resistance. Developing bispecific antibodies that redirect T cell killing toward CD30-positive tumors offers a potentially more effective and better-tolerated alternative — provided the right epitope is targeted. This study demonstrates that epitope location is not merely a characterization parameter but a functional determinant of bispecific antibody performance, directly influencing T cell activation and tumor cell killing potency. The selection of candidates with epitope profiles distinct from existing clinical antibodies also reduces the risk of competitive interference and may offer differentiated therapeutic advantages in refractory and relapsed disease settings.

How peptide microarrays were used: Overlapping peptide sequences spanning the CD30 extracellular domain were displayed on microarrays to map the linear binding regions recognized by each candidate antibody at high resolution. This enabled differentiation of antibodies targeting distinct epitope clusters and directly informed candidate selection by linking epitope location to functional behavior in downstream bispecific formats. Candidates with unique epitope profiles, differing from those of clinically established antibodies, were identified and prioritized. Microarray-derived epitope data were integrated with affinity measurements and functional assay results — including T cell activation and tumor cell killing readouts — establishing a clear mechanistic link between antigen recognition site and therapeutic potency, and supporting rational selection of lead candidates for bispecific engineering. 

Reference: Faber, Mary L., et al. “Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.” Frontiers in Immunology 14 (2023): 1225610.
https://doi.org/10.3389/fimmu.2023.1225610 

6. Mapping anti-drug antibody responses: Peptide microarrays reveal immunogenicity patterns in brolucizumab

Overview: Scientists at the Novartis Institutes for BioMedical Research applied peptide microarrays to characterize anti-drug antibody (ADA) responses against brolucizumab, a therapeutic antibody used in retinal disease, with the goal of understanding immunogenicity and its link to rare adverse events including retinal vasculitis and vascular occlusion. A comprehensive library of overlapping 15-mer peptides covering the full brolucizumab sequence was printed onto microarrays, and patient sera from the HAWK and HARRIER clinical trials, clinical practice samples, healthy donor samples, and preclinical models were screened to map linear ADA binding regions across the entire molecule. The analysis revealed a polyclonal, partially preformed ADA response targeting multiple epitopes distributed across both CDRs and framework domains, with no association identified between specific linear epitopes and adverse clinical outcomes.

Why this matters: Brolucizumab was associated with rare but serious ocular adverse events following its clinical introduction, raising urgent questions about the immunogenic mechanisms underlying these safety signals. Understanding whether specific ADA epitopes drive toxicity is critical for risk stratification, patient monitoring, and the rational optimization of therapeutic antibody design. The finding that epitope specificity does not correlate with adverse outcomes shifts attention toward other contributing factors — such as antibody titers or cellular immune responses — and provides important mechanistic clarity for the field. More broadly, the identification of preexisting, broadly shared immune recognition profiles against CDR and framework regions has implications for immunogenicity prediction and mitigation strategies in antibody drug development.

How peptide microarrays were used: A library of overlapping 15-mer peptides with single amino acid shifts, covering the complete brolucizumab sequence, was synthesized onto microarrays to enable systematic, sequence-resolved epitope mapping across the full molecule. Patient sera from clinical trials, clinical practice, healthy donors, and preclinical models were incubated on the arrays to identify linear regions recognized by ADAs. This approach revealed that individual patients recognize on average two to three distinct epitopes, with binding distributed across CDRs and framework domains. Frequently recognized sequence motifs, including regions within CDR2, were identified across a large fraction of samples, indicating broadly shared preexisting immune recognition. Epitope patterns were compared across patient subgroups — including those with and without adverse events — enabling direct assessment of whether linear epitope specificity correlates with clinical toxicity, and thereby contributing mechanistic insight essential for immunogenicity risk assessment. 

Reference: Karle, Anette C., et al. “Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.” Science Translational Medicine 15.681 (2023): eabq5241.
https://doi.org/10.1126/scitranslmed.abq5241 

How peptide microarrays accelerate therapeutic antibody development

Across these six case studies, peptide microarrays demonstrate their value as a high-resolution engine for therapeutic antibody discovery and optimization. From precise epitope mapping and specificity profiling to cross-reactivity assessment and immunogenicity risk evaluation, peptide microarrays provide the detailed molecular insights needed to move antibody candidates forward with confidence.

If you are looking to improve the precision and efficiency of your antibody R&D program, peptide microarrays offer a powerful platform to turn binding data into better therapeutics.

Contact PEPperPRINT today to explore how peptide microarrays can accelerate your antibody development.

← Go back